Speaker illustration

Doctor Goran Loncar

Institute for Cardiovascular Diseases Dedinje, Belgrade (Serbia)

Member of:

Goran Loncar is interventional cardiologist and heart failure specialist working at the Institute for cardiovascular diseases Dedinje, Belgrade, Serbia. As assistant of professor he educates students in Internal medicine at the School of Medicine, University of Belgrade. Dr Loncar has finished the School of medicine University of Belgrade as one the best students (average mark 9.91 out of 10). Afterwards he finished MSc and PhD studies at the same faculty with more than 40 publications in the journals of SCI. His RG score is 33.43 with h-index 12. Curently, he is attending postgraduate studies in heart failure (PCHF) at the University of Zurich endorsed by ESC academy (2018-2019). Dr Loncar has been trained several times at the Institute of Cardiology Pitié-Salpêtrière UPMC Sorbonne Universités (Paris, France): as a resident in cardiology in 2007/2008, as a fellow in interventional cardiology (ESC training grant) in 2014, following by the training in endomyocardial biopsy in 2018.

Sarcopenia in non-cachectic males with heart failure

Event: ESC CONGRESS 2019

Topic: Peripheral Circulation, Metabolism, Skeletal Muscle

Session: Cardiometabolic

Thumbnail

Osteoporosis in males with heart failure: impact on survival.

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Peripheral Circulation, Metabolism, Skeletal Muscle

Session: Chronic Heart Failure - Clinical

Thumbnail

Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction

Event: ESC CONGRESS 2016

Topic: Peripheral circulation, metabolism and skeletal muscle

Session: Best Posters in heart failure metabolism

Thumbnail

Hyperparathyroidism and its prognostic role in men with chronic heart failure

Event: HEART FAILURE 2016

Topic: Prognosis (using biomarkers)

Session: Moderated Poster Session 3 - Top news on Biomarkers

Thumbnail

This platform is supported by

logo Novo Nordisk